Add listing
    0
    Add listing

    Limula and its partners win highly competitive Eurostars grant Verified listing

    • Friday, April 15, 2022 @ 8:00 am

    With over EUR 1 million, the funding will allow the consortium to further improve the automated solution for end-to-end production of CAR T cell therapies developed by Limula

    Limula received a positive evaluation for its grant proposal entitled “Closed and Automated Manufacturing of CAR T-Cell Therapies”. The Lausanne-based startup will lead a consortium that includes Ceidos, another Swiss startup company developing the C-NETICS on-line and real-time cell analysis module, and Stemmatters, a private regenerative medicine company based in Barco, Portugal, providing contract development and manufacturing services for cell-based products and biologics.

    This European grant contributed in part by Innosuisse will allow Limula to augment its existing automated solution for end-to-end production of CAR T cell therapies with cell analytics capabilities provided by Ceidos. The aim of this collaboration is to combine Limula and Ceidos’ technologies into a complementary product offering, while leveraging Stemmatters’s expertise in cell therapy process development and cGMP manufacturing, towards fully closed and automated manufacturing of cell-based immunotherapies.

    You may also be interested in